par mp@atcg-partners.com | Oct 8, 2025 | Uncategorized
We are delighted to announce that HEPHAISTOS-Pharma has been honored with the Best Pitch nomination in the Biotech category at the 2025 HealthTech Innovation Days (HTID), organized by HealthTech For Care. HTID is one of Europe’s premier health-innovation gatherings,...
par Paul Saltet | Déc 10, 2024 | Uncategorized
HEPHAISTOS-Pharma has the honor to be a winner of a Golden Ticket from Amgen France x BioLabs Hôtel-Dieu in Paris. We have won one year of free residency at BioLabs Hôtel-Dieu and personalized mentorship from Amgen experts to accelerate the development of our...
par Paul Saltet | Déc 5, 2024 | Uncategorized
HEPHAISTOS-Pharma was laureate of the Hack4Hope, the hackathon against pediatric cancer following a great day of speed dating with pharmas, patients’ associations and experts in childhood cancer The jury was composed of experts in Oncology and Childhood cancer from...
par Paul Saltet | Mai 16, 2024 | Uncategorized
HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led by Elaia with xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business...
par Paul Saltet | Mar 14, 2024 | Uncategorized
Our CEO, Frederic CAROFF will be attending BIO-Europe Spring 2024 in Barcelona from March 18th to 20th. He will meet series A investors interested in Oncology biotech companies developing game-changing immunotherapy platform. He will also discuss with Pharmaceutical...
par Paul Saltet | Jan 23, 2024 | Uncategorized
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic. ONCO-Boost is a novel class of TLR4...
